Choose an Icon to Learn More:
Providing low-income Denver children with the eye care and corrective eyewear they need to be their best in the classroom and in life.
The mission of Von's Vision is to provide low-income Denver children with the eye care and corrective eyewear they need to be their best in the classroom and in life. According to recent data collected by Von’s Vision, 38% of children in the United States need some form of vision correction. Three out of every ten children under six years old have never been seen by an eye doctor for a variety of reasons. Von’s Vision will work to provide solutions to this problem through development of targeted and strategic impact and outreach programs.
Dr. Kirk Matoba offers Medical Eye & Vision Care Services, Low vision evaluation and management for pediatric to geriatric care, and Trial Frame refraction Contrast/tint testing.
Dr. Kirk Matoba is a third generation optometrist with interest in Neuro/head trauma as well as Low Vision and partially sighted. Dr. Emily Matoba has experience in low vision and pediatric exams. She has worked with The William Feinbloom Rehabilitation Center at the Eye Institute as well as perform vision screening for children in The Overbrook School of the Blind. We have been in practice since 1986, and practice solely in Lakewood since 2002. Today we provide comprehensive vision and medical exams. Our Low Vision services include: Trial Frame refraction, contrast/tint testing. Trialing eschenbach low vision devices such as magnifiers, telescopes, maxTv, Max details. We have an OCT and VF for any immediate need. We also have a consult for Orcam to come in and talk about the device with the patient and family.
Providing comprehensive early educational services for infants and children who are blind or visually impaired.
No-cost Eye assessments for infants 6-12 months of age. The American Optometric Association recommends scheduling an infant's first eye exam around six months of age, immediately after the eye undergoes rapid and profound changes and is therefore most vulnerable to interference with healthy development.
Tech for Tykes is a groundbreaking program that is changing the lives of young children with disabilities through the use of assistive technology (AT).
Tech for Tykes is a groundbreaking program that is changing the lives of young children with disabilities through the use of assistive technology (AT). Children with developmental delays or disabilities often have difficulty playing and interacting with the world around them. AT provides them with opportunities to be active participants in life rather than passive bystanders. We hope you will take some time to explore the many valuable tools and resources Tech for Tykes has to offer children, families, caregivers and providers in the early childhood community.
A virtual program offered to the ocular melanoma (OM) community, as a platform for hope, education, mental wellness, resource sharing, support and camaraderie to allow you to not just survive, but thrive.
Colorado Retina in conjunction with the Melanoma Research Foundation's CURE OM initiative and the University of Denver Center for Oncology Psychology Excellence (C.O.P.E.) recognize that disease treatment extends to the well-being of the whole patient. The Ocular Melanoma Support Alliance (OMSA) is a virtual program offered to the ocular melanoma community, as a platform for hope, education, mental wellness, resource sharing, support and camaraderie to allow you to not just survive, but thrive.
In our April monthly edition of OMSA, we welcome guest presenter, Dr. Meredith McKean, Associate Director of Melanoma and Skin Cancer Research at the SarahCannon Research Institute at Tennessee Oncology. Sarah Cannon offers 25 practice locations, 8 of which are oncology sites and staff as a whole over 250 medical oncologists who comprehensively manage 75,000+ new tumor patients each year. At Sarah Cannon, Dr. McKean and her team focus on identifying genetic drivers of each person's individual cancer through a personalized medicine approach. Dr. McKean will jump into the capabilities and experience her team has within conducting investigational therapy clinical trials for uveal melanoma and how understanding melanoma as a whole is pivotal to finding what other treatments researchers need to add to immunotherapy to make cancers respond to treatment. She will also cover the significant strides molecular profiling and targeted therapies have made to increase the survival rate for metastatic melanoma.
We will conclude with an open group discussion moderated by trained mental health professionals who will facilitate a conversation around the emotional, mental, and lifestyle aspects of an OM diagnosis.
WHO: This meeting is for all patients diagnosed with any form of ocular melanoma; complimentary admission for all
CONTACT: Amanda Sisco, email@example.com, (720) 420-3271
If you are no longer able to make the meeting, please make sure you cancel your Eventbrite ticket. Spots are limited.
We look forward to virtually seeing you there!